MLYS — Mineralys Therapeutics, Inc.

Summary of Mineralys (MLYS) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Mineralys reported cash, cash equivalents, and investments of $593.6 million, a significant increase from $198.2 million at the end of 2024. This cash is expected to fund operations into 2028.
• R&D Expenses: Decreased to $31.5 million from $54 million in Q3 2024, primarily due to the conclusion of pivotal trials for lorundrostat.
• G&A Expenses: Increased to $9.7 million from $6.1 million in Q3 2024, driven by higher compensation and professional fees.
• Net Loss: Reported at $36.9 million, down from $56.3 million in the prior year, reflecting improved expense management.

2. Strategic Updates and Business Highlights

• NDA Submission: The company is on track to submit a New Drug Application (NDA) for lorundrostat by late Q4 2025 or early Q1 2026, following positive pre-NDA feedback from the FDA.
• Clinical Trials: Positive results from pivotal trials (Launch-HTN and Advance-HTN) demonstrate lorundrostat's effectiveness in reducing systolic blood pressure in diverse patient populations, including those with resistant hypertension.
• New Trials: Enrollment is complete for the Explore-OSA trial, which evaluates lorundrostat in patients with obstructive sleep apnea and hypertension, with results expected in Q1 2026.
• Market Access: The company is prioritizing market access planning and payer engagement to ensure the value of lorundrostat is understood ahead of its launch.

3. Forward Guidance and Outlook

• Mineralys is confident in the strength of its clinical data and plans to advance lorundrostat as a best-in-class treatment for uncontrolled hypertension and related comorbidities.
• The company anticipates continued progress in its clinical programs and is preparing for commercialization efforts.

4. Bad News, Challenges, or Points of Concern

• Data Handling: There are concerns regarding the handling of missing data in clinical trials, particularly in relation to FDA requirements for analysis. The company has not performed certain analyses that could impact perceived efficacy.
• Competitive Landscape: The presence of competitors like AstraZeneca, which has highlighted its product's longer half-life, poses a challenge. The company needs to differentiate lorundrostat effectively in a competitive market.
• Diversity in Trials: Although Mineralys has made strides in including diverse populations in its trials, the competitive landscape may still affect perceptions of efficacy across different demographic groups.

5. Notable Q&A Insights

• Efficacy Analysis: During Q&A, executives clarified that they have not conducted analyses excluding discontinuations in their studies, emphasizing the importance of including all enrolled subjects in the results.
• Partnership Discussions: The company is open to partnerships for both U.S. and international commercialization, aiming to maximize the value of lorundrostat.
• Response Rates: In the Launch-HTN trial, 44% of patients reached blood pressure goals at week 6, while 42% achieved this in the Advance-HTN trial at week 4, indicating promising efficacy.
• Diversity in Patient Populations: Executives highlighted that lorundrostat demonstrated consistent efficacy across diverse racial groups, addressing concerns about underrepresentation in clinical trials.

Overall, Mineralys is positioned for potential growth with lorundrostat, backed by strong clinical data and a solid financial foundation, though it faces challenges in data management and competitive pressures.